Systemic treatment of renal cell cancer: A comprehensive review

Sánchez-Gastaldo, Amparo; Kempf, Emmanuelle; Alba, Aránzazu Gonzalez del; Durán, Ignacio

doi:10.1016/j.ctrv.2017.08.010

Cited by 134 publications

(105 citation statements)

References 105 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…Another challenge in KCa relates to its chemo-and radioresistance. Targeted therapies against VEGFR and the mTOR pathway have changed the paradigm of metastatic RCC [74]. However, the challenge is that patients develop resistance to these agents over time [75,76], so novel therapies are needed.…”

Section: Major Clinical Challengesmentioning

confidence: 99%

Targeting the Immune system and Epigenetic Landscape of Urological Tumors

Lobo

Jerónimo

Henrique

2020

IJMS

View full text Add to dashboard Cite

In the last years, we have witnessed remarkable advances in targeted therapies for cancer patients. There is a growing effort to either replace or reduce the dose of unspecific, systemic (chemo)therapies, given the associated short- and long-term side effects, by introducing more specific targeted therapies as single or combination agents. Due to the well-known implications of the immune system and epigenetic landscape in modulating cancer development, both have been explored as potential targets in several malignancies, including those affecting the genitourinary tract. As the immune system function is also epigenetically regulated, there is rationale for combining both strategies. However, this is still rather underexplored, namely in urological tumors. We aim to briefly review the use of immune therapies in prostate, kidney, bladder, and testicular cancer, and further describe studies providing supporting evidence on their combination with epigenetic-based therapies.

show abstract

Section: Major Clinical Challengesmentioning

confidence: 99%

Targeting the Immune system and Epigenetic Landscape of Urological Tumors

Lobo

Jerónimo

Henrique

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…A number of novel drugs based on molecular targets relating to the progression of renal cell carcinoma (RCC) have been developed and used in clinical practice, drastically improving the prognosis of patients with metastatic RCC [1,2]. However, specific adverse reactions which are not popular in the treatment with ordinal cytotoxic cancerous drugs are being reported [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma

Yamamoto

Yano

2018

Med Oncol

View full text Add to dashboard Cite

The prognosis of patients with metastatic renal cell carcinoma has drastically improved due to the development of molecular-targeted drugs and their use in clinical practice. However, these drugs cause some diverse adverse reactions in patients and sometimes affect clinical outcomes of cancer therapy. Therefore, predictive markers are necessary to avoid severe adverse reactions, to establish novel and effective prevention methods, and to improve treatment outcomes. Some genetic factors involved in these adverse reactions have been reported; however, perspectives on each adverse response have not been integrated yet. In this review, genetic polymorphisms relating to molecular-targeted therapy-induced adverse reactions in patients with renal cell carcinoma are summarized in the points of pharmacokinetic and pharmacodynamic mechanisms. We also discuss about the relationship between systemic drug exposure and adverse drug reactions.

show abstract

“…Recently, in addition to cytotoxic agents, molecular-targeted drugs and immune checkpoint inhibitors have been introduced as new treatment options in patients with urological cancers, such as metastatic RCC and metastatic UC. [24][25][26] The role of molecular markers in appropriate patient selection has also been investigated. 27 Even in such circumstances, there have been an increasing number of clinical studies evaluating the role of SIR markers in cancer patients.…”

mentioning

confidence: 99%

Role of systemic inflammatory response markers in urological malignancy

Ohno

2018

Int J of Urology

View full text Add to dashboard Cite

The systemic inflammatory response is associated with survival in patients with a variety of cancers. This inflammatory response is measured in the peripheral blood, and can be monitored using two categories of indices: concentration of specific serum proteins (albumin, C‐reactive protein) and differential blood cell count (neutrophils, lymphocytes and platelets). Furthermore, combinations of these indices, such as the Glasgow Prognostic Score, which consists of the serum C‐reactive protein and albumin level; the neutrophil‐to‐lymphocyte ratio; the platelet‐to‐lymphocyte ratio; and the prognostic nutritional index, which is based on peripheral blood lymphocyte count and serum albumin level, have also been evaluated and compared in cancer research. To date, there are hundreds of studies that have shown the prognostic value of systemic inflammatory response markers in patients with urological cancer. Most studies have evaluated the prognostic and predictive role of the pretreatment value of the markers, although some have focused on the role of the post‐treatment value at specific points during the clinical course. The advantages of systemic inflammatory response markers are that they are easily measurable and inexpensive in the clinical setting. However, it is important to consider how clinicians use these markers in clinical practice. The present review provides a concise overview regarding systemic inflammatory markers in urological cancers, specifically C‐reactive protein, Glasgow Prognostic Score/modified Glasgow Prognostic Score, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio and prognostic nutritional index.

show abstract

Systemic treatment of renal cell cancer: A comprehensive review

Cited by 134 publications

References 105 publications

Targeting the Immune system and Epigenetic Landscape of Urological Tumors

Targeting the Immune system and Epigenetic Landscape of Urological Tumors

Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma

Role of systemic inflammatory response markers in urological malignancy

Contact Info

Product

Resources

About